Berberine can reverse doxorubicin resistance in breast cancer cells by regulating the PI3K/Akt pathway, and it can further attenuate autophagy by reducing the number of autophagosomes, enhancing the expression of p62, and inhibiting the expression of multidrug resistance protein 1 [33]. Here, AKT1 is linked to breast carcinoma.